Entelos yesterday said that it has acquired toxigenomics firm Iconix Biosciences in an all-share transaction initially valued at $14.1 million but with the potential of rising to $39 million.

 

Foster City, Calif.-based Entelos said that it would issue up to 12,776,658 shares of its stock to Iconix shareholders and a potential maximum earn-out payment of $25 million if certain milestones are achieved within one year following the close of the deal today. The deferred consideration also would be paid in Entelos shares.